Literature DB >> 2088208

Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro.

G Andrei1, E De Clercq.   

Abstract

Several compounds, belonging to different classes of nucleoside analogues and sulfated polysaccharides, were evaluated for their inhibitory effects on the replication of the arenaviruses Junin and Tacaribe in VERO cells. S-Adenosylhomocysteine (AdoHcy) hydrolase inhibitors [i.e. adenosine dialdehyde, carbocyclic 3-deazaadenosine (C-c3 Ado), neplanocin A, 3-deazaneplanocin A, 9-(2,3-dihydroxypropyl)adenine [(S)-DHPA], (RS)-3-adenin-9-yl-hydroxypropanoic acid isobutyl ester [(RS)-AHPA], the 2',3'-dihydroxycyclopentenyl derivatives of adenine (DHCA) and 3-deazaadenine (DHCDA)] inhibited arenavirus replication within the concentration range of 1-10 micrograms/ml, while not being toxic for cell morphology or cellular DNA synthesis at a concentration of 100-400 micrograms/ml. Based on the ratio of the concentrations required to inhibit cell proliferation and virus replication, only (S)-DHPA, DHCA, C-c3 Ado and adenosine dialdehyde could be considered as truly selective inhibitors. Tubercidin, cyclopentenyl cytosine, pyrazofurin and ribavirin also inhibited viral cytopathogenicity at concentrations that were well below the cytotoxic threshold. Carbodine (cyclopentyl cytosine) also proved to be a potent inhibitor of arenavirus replication, but it was not as selective as cyclopentenyl cytosine. Very potent and selective inhibitors were the sulfated polysaccharides dextran sulfate, lambda-carrageenan, fucoidan, heparin and pentosan polysulfate: they inhibited virus replication at a concentration of 0.1-2.8 micrograms/ml, whereas the compounds were not inhibitory to cell growth even at a concentration of 200 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2088208     DOI: 10.1016/0166-3542(90)90009-v

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  23 in total

Review 1.  Novel approaches in anti-arenaviral drug development.

Authors:  Andrew M Lee; Antonella Pasquato; Stefan Kunz
Journal:  Virology       Date:  2010-12-22       Impact factor: 3.616

2.  Replicon system for Lassa virus.

Authors:  Meike Hass; Uta Gölnitz; Stefanie Müller; Beate Becker-Ziaja; Stephan Günther
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Sulfated polyanions do not inhibit duck hepatitis B virus infection.

Authors:  W B Offensperger; S Offensperger; E Walter; H E Blum; W Gerok
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine.

Authors:  Justin G Julander; Richard A Bowen; Jagadeeshwar R Rao; Craig Day; Kristiina Shafer; Donald F Smee; John D Morrey; Chung K Chu
Journal:  Antiviral Res       Date:  2008-08-15       Impact factor: 5.970

5.  Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins.

Authors:  M Hosoya; J Balzarini; S Shigeta; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

6.  Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection.

Authors:  M C Georges-Courbot; H Contamin; C Faure; P Loth; S Baize; P Leyssen; J Neyts; V Deubel
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

7.  Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds.

Authors:  E De Clercq; M Cools; J Balzarini; R Snoeck; G Andrei; M Hosoya; S Shigeta; T Ueda; N Minakawa; A Matsuda
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

8.  T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.

Authors:  J O Ojwang; R W Buckheit; Y Pommier; A Mazumder; K De Vreese; J A Esté; D Reymen; L A Pallansch; C Lackman-Smith; T L Wallace
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  Comparative activity of various compounds against clinical strains of herpes simplex virus.

Authors:  G Andrei; R Snoeck; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

Review 10.  Reverse genetics approaches to combat pathogenic arenaviruses.

Authors:  Juan C de la Torre
Journal:  Antiviral Res       Date:  2008-09-07       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.